In the latest trading session, Pfizer (PFE) closed at $23.72, marking a -2.47% move from the previous day. The stock trailed ...

Pfizer's IBRANCE has received new FDA approval as the first CDK4/6 inhibitor maintenance therapy for HR+, HER2+ metastatic ...

NVO trades at a forward P/E of 14 and PFE at just 8x, making both the cheapest large-cap healthcare names despite strong ...

Eli Lilly & Company LLY and Pfizer PFE are large-cap U.S. drugmakers supported by broad product portfolios and strong ...

Pfizer’s valuation story turns to pipeline progress, oncology pressure, earnings strength, and healthcare execution after a ...

Pfizer Inc. (NYSE:PFE) is one of the best dividend stocks to buy, according to hedge funds. On June 24, the US Food and Drug ...

Pfizer (PFE) closed at $24.08 in the latest trading session, marking a -1.19% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.79%. At the same time, the Dow ...

Pfizer Inc gains attention as pipeline expansion, metabolic medicine, oncology progress and regulatory developments keep the ...

Is PFE a good stock to buy? We came across a bullish thesis on Pfizer Inc. on r/ValueInvesting by Dismal-Cancel4958. In this ...

After losing nearly half its value from its 2021 highs, Pfizer stock (NYSE: PFE) now trades at about $25, presenting a potentially attractive value setup. As the company continues to adapt to a ...

Pfizer stock (NYSE: PFE) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $17.8 billion and adjusted earnings of $0.63 per ...

The U.S. Food and Drug Administration approved the use of Ibrance as maintenance treatment for adults with a specific type of ...